Insmed Inc’s recently made public that its Chair and CEO Lewis William unloaded Company’s shares for reported $1.79 million on Dec 18 ’25. In the deal valued at $166.97 per share,10,699 shares were sold. As a result of this transaction, Lewis William now holds 303,911 shares worth roughly $53.14 million.
Then, William Lewis bought 10,699 shares, generating $1,786,437 in total proceeds.
Before that, SHAROKY MELVIN MD sold 20,000 shares. Insmed Inc shares valued at $4,100,200 were divested by the Director at a price of $205.01 per share. As a result of the transaction, SHAROKY MELVIN MD now holds 243,948 shares, worth roughly $42.65 million.
A number of analysts have revised their coverage, including Rothschild & Co Redburn’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Wells Fargo started covering the stock on October 20, 2025. It rated INSM as “an Overweight”.
Price Performance Review of INSM
On Friday, Insmed Inc [NASDAQ:INSM] saw its stock jump 4.98% to $174.84. Over the last five days, the stock has lost -11.25%. Insmed Inc shares have risen nearly 136.75% since the year began. Nevertheless, the stocks have risen 153.24% over the past one year. While a 52-week high of $212.75 was reached on 12/02/25, a 52-week low of $60.40 was recorded on 04/09/25.
Levels Of Support And Resistance For INSM Stock
The 24-hour chart illustrates a support level at 168.30, which if violated will result in even more drops to 161.75. On the upside, there is a resistance level at 179.80. A further resistance level may holdings at 184.75.
How much short interest is there in Insmed Inc?
A steep rise in short interest was recorded in Insmed Inc stocks on 2025-11-28, growing by 1.83 million shares to a total of 9.87 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 8.03 million shares. There was a rise of 18.58%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 20, 2025 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating.
